annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 11H Reproductive history and risk of colorectal cancer in postmenopausal
women. (Abstract #3618)
A. Zervoudakis, A. Schatzkin, H. D. Strickler, Y. Park, A. Hollenbeck, M. J. Gunter
Brd. 12A The effect of opposed versus unopposed hormone replacement therapy
(HRT) on the risk of colorectal cancer (CRC). (Abstract #3619)
K. Lin, W. Y. Cheung, J. Y. Lai, E. L. Giovannucci
Brd. 12B Guideline adherence rates of chemotherapy treatment for colon cancer
patients treated in U.S. community oncology practices. (Abstract #3620)
Z. Wang, K. A. Bergstrom, I. Aksamit, L. Tuscher, T. Lam, B. S. Tom, C. G. Baker,
K. B. Whitlock, Z. Ansari-Jaberi, M. Mayo
Brd. 12F Presurgical diagnostic accuracy of five imaging procedures in
chemotherapy-naive (group A) or chemotherapy-pretreated (group B)
patients with colorectal liver metastases (Italian PROMETEO Study).
(Abstract #3621)
F. L. Rojas Llimpe, F. Di Fabio, G. Ercolani, C. Serra, P. Castellucci, S. Pini,
V. Mutri, R. Golfieri, A. Martoni, C. Pinto
Brd. 12G Dietary grape-derived resveratrol for colon cancer prevention. (Abstract
#3622)
M. Martinez, C. Hope, K. Planutis, M. Planutiene, A. Pontello, B. Duarte,
C. G. Albers, R. F. Holcombe
Brd. 12H Cost-effectiveness analysis of the addition of bevacizumab to first-line
chemotherapy in metastatic colorectal cancer. (Abstract #3623)
D. Villa, L. Hedden, S. Peacock, H. F. Kennecke
Brd. 13A Association of survival outcomes with dose intensity of adjuvant therapy
(AT) with capecitabine for colorectal cancer (CRC). (Abstract #3624)
J. Ho, S. Gill, R. Woods, H. F. Kennecke
Brd. 13B Characterize medical care during disease phases in metastatic colorectal
cancer. (Abstract #3625)
X. Song, B. Barber, Z. Zhao, C. Gregory, Z. Cao
Brd. 13C Use of an electronic health record (iKnowMed), in conjunction with evidencebased
pathways, for data capture and outcome measurement in colorectal
cancer patients treated with first-line therapy in the US Oncology Network.
(Abstract #3626)
T. H. Cartwright, M. Clayton, J. S. Garey, K. A. Boehm
Brd. 13D Spectrum of colon polyposis and colonic neoplasia in the PTEN hamartoma
tumor syndrome (PHTS). (Abstract #3627)
P. P. Stanich, S. Khambatta, S. R. Sweetser, R. L. Richardson, M. P. Goetz,
M. M. Patnaik
Brd. 13E Treatment patterns in patients with colorectal liver metastasis: A cohort
study. (Abstract #3628)
D. A. Anaya, P. A. Richardson, D. Albo, A. Artinyan, N. J. Petersen, S. S. Awad,
D. H. Berger, J. N. Cormier
Brd. 13F The awareness and knowledge levels of colorectal cancer (CRC) patients and
their first-degree relatives (FDR) for CRC screening. (Abstract #3629)
C. Arslan, S. Kilickap, D. Rama, S. Yalcin
Brd. 13G To detect Lynch syndrome patients, which colorectal cancers should be
tested for microsatellite instability? (Abstract #3630)
B. M. Boman, K. Orio, N. J. Petrelli, M. Parker, C. Somerman, Z. Ali-Khan Catts
Brd. 13H A novel, noninvasive, mRNA gene expression colon cancer screening
methodology. (Abstract #3631)
L. A. Boardman, Y. S. Chiu, O. Petrauskene, L. Wieczorek, D. H. Moore,
K. V. Ballman, S. N. Thibodeau, H. Nelson
Brd. 14A Results of a German noninterventional study (NIS) of cetuximab-based
therapy in pretreated patients (pts) with metastatic colorectal cancer
(mCRC). (Abstract #3632)
C. Jehn, K. Stenzel, L. Böning, H. Kröning, K. Possinger, D. Lueftner
263
SUNDAY